Viewing StudyNCT00452075



Ignite Creation Date: 2024-05-05 @ 5:27 PM
Last Modification Date: 2024-10-26 @ 9:31 AM
Study NCT ID: NCT00452075
Status: TERMINATED
Last Update Posted: 2014-12-11
First Post: 2007-03-23

Brief Title: Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer NSCLC for Patients Unfit for Chemotherapy
Sponsor:
Organization: Rigshospitalet Denmark

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 24
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE2
Observational Models:
Time Perspective List:
Who Masked List: